ABBVIE INC
4,475 institutions still hold ABBVIE INC as of Q2 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
ABBV registers 3,919 institutional filers with roughly $272B in aggregate 13F value, and the register tells a two-layer story: a standard passive core of BlackRock, Vanguard, State Street, and FMR beneath a thin but analytically meaningful active pharmaceutical layer. The defining ABBV signal is not current positioning but pipeline-watch behavior: Capital Research Global Investors and Wellington Management maintain meaningful stakes as options-market sensitives, signaling that bottom-up allocators continue to treat AbbVie immunology and oncology franchises as durable despite Humira biosimilar erosion.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.